AI Is Now Denying 1 in 4 Insurance Claims — The ‘Battle of the Bots’ Lands at HIMSS Next Month

A quiet revolution is underway in American healthcare—and it is about to erupt onto the trade show floor. Medicare’s “Wasteful and Inappropriate Service Reduction Model” went live in January 2026, deploying artificial intelligence to pre-screen claims across 14 categories of medical procedures in six states. Simultaneously, private insurers have accelerated their own AI-powered denial engines to the point where roughly 1 in 4 insurance claims are now being rejected at some plans, with denial rates running between 20% and 25%. The American Medical Association reports that 61% of physicians are concerned that health plan AI is increasing prior authorization denials. And in a development that perfectly captures the absurdity of the moment, providers are now deploying their own AI systems to fight back against insurer AI—a dynamic the industry has grimly dubbed the “battle of the bots.” When HIMSS opens its doors next month, this collision of algorithms, regulation, and patient care will dominate every conversation on the show floor.

Medicare’s AI Denial Machine: What the Model Actually Does

The program carrying the bureaucratically antiseptic name “Wasteful and Inappropriate Service Reduction Model” represents the federal government’s first large-scale deployment of artificial intelligence for claims adjudication. Launched in January 2026 across six states, the model uses machine learning algorithms to pre-screen Medicare claims against 14 categories of procedures that the Centers for Medicare & Medicaid Services has identified as having high rates of unnecessary utilization. Claims flagged by the AI are subjected to additional review before payment is authorized, effectively adding an algorithmic gatekeeper between providers and reimbursement.

The categories targeted by the model span a broad range of medical services, from diagnostic imaging and laboratory tests to post-acute care placements and durable medical equipment. For healthcare IT vendors, the implications are immediate: every electronic health record system, every revenue cycle management platform, and every clinical decision support tool now needs to account for the reality that a federal AI may be evaluating the medical necessity of the procedures their software helps document and bill.

What makes this development particularly significant for the trade show circuit is its timing. The model launched just weeks before HIMSS 2026, the largest healthcare information technology conference in the world. Exhibitors who planned their booth messaging six months ago are now scrambling to incorporate AI claims denial into their value propositions. Those who anticipated this shift are positioned to dominate the conversation.

“We are witnessing the most significant structural change in claims adjudication since the introduction of diagnosis-related groups in 1983. Except this time, the decision-maker is an algorithm—and it operates at a scale and speed that no human review process can match.”

The Private Insurer Acceleration: 20–25% Denial Rates

While Medicare’s AI program captures headlines, the private insurance industry has been quietly building its own algorithmic denial infrastructure for years—and the results are now measurable and alarming. At some health plans, AI-powered systems are denying roughly 1 in 4 claims, pushing rejection rates into the 20% to 25% range. These are not marginal increases. They represent a fundamental acceleration in the speed and volume at which coverage determinations are being made—or more precisely, being refused.

The mechanics are straightforward but consequential. Insurers train machine learning models on historical claims data, identifying patterns associated with procedures they consider potentially unnecessary or insufficiently documented. When a new claim arrives, the AI evaluates it against these patterns in milliseconds and issues a determination. The human reviewer who might have spent minutes or hours evaluating clinical context, patient history, and medical necessity has been replaced by an algorithm that processes thousands of claims per hour.

For providers, the financial impact is severe. Denied claims do not simply disappear—they enter an appeals process that consumes staff time, generates administrative overhead, and delays revenue. The American Medical Association’s survey finding that 61% of physicians are concerned about AI increasing prior authorization denials understates the operational reality. Behind that statistic are billing departments working overtime, revenue cycle teams managing growing appeals backlogs, and clinical staff spending hours on peer-to-peer reviews that should be unnecessary.

The ‘Battle of the Bots’ Arrives on the Show Floor

Perhaps the most striking development in this landscape is the emergence of what industry insiders call the “battle of the bots”—providers deploying their own AI systems to counter insurer AI denials. The logic is compelling: if insurers can use algorithms to deny claims at unprecedented speed and volume, providers need algorithms of equal sophistication to identify denial patterns, optimize documentation, and automate appeals.

The evidence that this approach works is already compelling. Mayo Clinic has cut approximately 30 full-time equivalent positions and saved $700,000 annually by deploying AI bots in its revenue cycle management operations. These bots handle tasks that previously required human staff: identifying undercoded procedures, flagging documentation gaps before claims are submitted, tracking denial patterns by payer and procedure type, and automating the initial stages of the appeals process. The savings are not theoretical—they are hitting Mayo’s bottom line today.

For HIMSS exhibitors, Mayo’s experience is both a proof point and a competitive threat. Revenue cycle management vendors who cannot demonstrate AI-powered denial prevention and appeals automation will find themselves at a significant disadvantage on the show floor. Buyers walking the HIMSS exhibit hall in March are not looking for incremental improvements to their billing workflows—they are looking for weapons in an algorithmic arms race that is already underway.

The battle of the bots creates a new category of trade show exhibitor: companies whose entire value proposition is fighting AI with AI. These vendors offer platforms that analyze denial patterns across payers, predict which claims are likely to be flagged by insurer algorithms, optimize clinical documentation to satisfy AI-driven medical necessity checks, and automate appeals with machine-generated narratives that address the specific reasons cited in denial letters. At HIMSS 2026, expect this category to command some of the largest and most heavily trafficked booths on the show floor.

Three States Draw a Legal Line—And Create a Compliance Market

The regulatory response to AI-driven claims denial has been swift at the state level. Texas, Arizona, and Maryland have all passed laws prohibiting the use of AI as the sole basis for medical necessity denials. These laws require that a licensed physician or qualified clinical reviewer evaluate any claim denial that was initially flagged by an algorithm, effectively mandating human oversight of AI decision-making in healthcare coverage determinations.

For healthcare IT trade show exhibitors, these state laws create an entirely new compliance market. Every insurer and health plan operating in Texas, Arizona, or Maryland now needs technology that can demonstrate human-in-the-loop review processes for AI-generated denials. Every provider in those states needs documentation that their appeals are being evaluated by humans, not algorithms. And every healthcare IT vendor selling claims management or prior authorization solutions needs to build state-specific compliance workflows into their platforms.

The legislative trend is accelerating. At least a dozen additional states have introduced similar bills in their 2026 legislative sessions, and federal legislation requiring human review of AI coverage decisions is advancing through committee. For exhibitors at HIMSS, AHIP, and HFMA, the compliance opportunity is substantial—but only for those who move quickly. The window between early adoption and commoditization of AI denial compliance tools is narrow, and the companies that establish themselves at trade shows in the first half of 2026 will have a significant head start.

“Three states have already drawn the line. A dozen more are following. The message to health plans is unambiguous: AI can inform coverage decisions, but it cannot make them unilaterally. For healthcare IT vendors, this is not a regulatory burden—it is a product roadmap.”

How This Reshapes the HIMSS Exhibit Hall

HIMSS has always been the healthcare IT industry’s defining event—the place where purchasing decisions are initiated, vendor relationships are established, and market narratives are set for the year ahead. But HIMSS 2026 arrives at a moment of unusual intensity. The convergence of Medicare’s AI denial program, soaring private insurer rejection rates, the battle of the bots, and a patchwork of new state regulations creates a show floor dynamic that will feel fundamentally different from previous years.

Several shifts are already visible in exhibitor registrations and booth configurations:

• Revenue cycle management vendors are expanding their footprints. Companies like R1 RCM, Waystar, and Change Healthcare are investing in larger booth spaces with dedicated demonstration areas for AI-powered denial management. The RCM section of the HIMSS exhibit hall will be the most heavily trafficked zone at the show.
• Prior authorization automation is the new must-have demo. Every EHR vendor, from Epic to Oracle Health to MEDITECH, will need to show how their platform handles AI-driven prior authorization workflows. Buyers are no longer interested in prior auth as a checkbox feature—they want to see real-time AI-to-AI interaction between their documentation systems and payer algorithms.
• Compliance and audit trail vendors are emerging from the margins. Companies offering AI explainability, decision audit trails, and regulatory compliance tools for the Texas-Arizona-Maryland framework are securing booth space for the first time at HIMSS. These vendors were niche players a year ago. They are now positioned at the center of the conversation.
• Clinical documentation improvement takes on new urgency. If insurer AI is evaluating medical necessity based on documentation patterns, then the quality and specificity of clinical documentation becomes a direct revenue driver. CDI vendors will frame their HIMSS presentations around denial prevention, not just coding accuracy.

Beyond HIMSS: The Ripple Across AHIP, HFMA, and ViVE

The AI claims denial story does not begin and end at HIMSS. Its implications radiate across the healthcare conference calendar, reshaping exhibitor strategies at multiple events throughout 2026.

AHIP Conference is where the payer perspective takes center stage. Health insurance executives who have invested billions in AI-driven utilization management will face pointed questions from regulators, providers, and patient advocates. Exhibitors at AHIP selling AI tools to insurers will need to demonstrate that their systems include human review workflows, comply with emerging state laws, and produce transparent, explainable decisions. The days of “our AI reduces unnecessary utilization” as a standalone pitch are over—payers now need to show that their AI is fair, auditable, and legally defensible.

HFMA Annual Conference is the financial counterpart to HIMSS’s technology focus. Healthcare CFOs and revenue cycle leaders attending HFMA are acutely aware that AI-driven denials are eroding their margins. The Mayo Clinic’s $700,000 savings figure will be referenced in dozens of HFMA presentations as proof that AI-powered revenue cycle management delivers measurable ROI. Exhibitors who can quantify the financial impact of their denial management solutions—in dollars saved, FTEs reallocated, and days in accounts receivable reduced—will command the most attention.

ViVE, the newer entrant on the healthcare conference circuit, has positioned itself as the home for health IT innovation and venture capital. The AI claims denial market is exactly the kind of rapidly evolving, high-stakes technology space that attracts both startups and investors. Expect ViVE 2026 to feature an unusually dense concentration of early-stage companies offering novel approaches to denial prediction, appeals automation, and AI compliance—and an equally dense concentration of health system innovation officers looking for solutions they can pilot immediately.

What This Means for Patients—And Why Exhibitors Should Care

Behind every denied claim is a patient. A patient whose surgery is delayed while an algorithm decides whether it is medically necessary. A patient whose medication is interrupted while a prior authorization appeal works its way through a queue. A patient who receives a surprise bill because their insurer’s AI determined that a procedure performed in an emergency was not covered. The human cost of algorithmic claims denial is real, measurable, and growing.

Trade show exhibitors who understand this dynamic have a strategic advantage. The most effective booth presentations at HIMSS, AHIP, and HFMA in 2026 will not be purely technical demonstrations of AI capabilities. They will connect technology to patient outcomes. They will show how faster appeals reduce treatment delays. They will demonstrate how better documentation prevents denials that leave patients with unexpected financial exposure. They will present data showing that AI-powered revenue cycle management does not just save hospitals money—it gets patients the care they need more quickly.

Strategic Playbook for Healthcare IT Exhibitors

The AI claims denial landscape is evolving faster than most exhibitors’ marketing cycles can accommodate. Here is what healthcare IT vendors should be doing right now to prepare for HIMSS and the broader 2026 conference season:

• Lead with denial rate data. Every booth visitor at HIMSS will have seen the “1 in 4” statistic. Open your conversations with specific, verified data about denial rates by payer, procedure, and geography. Generic claims about “reducing denials” will not cut through—you need numbers that match your prospect’s specific pain points.
• Demonstrate AI-to-AI workflows. The battle of the bots is real. Buyers want to see live demonstrations of your AI analyzing a denial from an insurer’s AI, identifying the specific reason for denial, cross-referencing against clinical documentation, and generating an optimized appeal. If your demo still shows a human manually reviewing a denial letter, you are behind.
• Build a compliance narrative for Texas, Arizona, and Maryland. These three states are just the beginning. Exhibitors who can show state-by-state compliance workflows for human-in-the-loop AI review will attract buyers from health plans operating across multiple jurisdictions. Make the compliance map part of your booth signage.
• Quantify ROI in Mayo Clinic terms. The $700,000 savings and 30 FTE reduction at Mayo Clinic is the benchmark every buyer will reference. If your solution delivers comparable or superior economics, prove it with customer data. If it does not, explain why your approach delivers value that Mayo’s model cannot capture.
• Prepare for the patient story. Expect media, analysts, and advocacy organizations to be present at HIMSS asking hard questions about how AI denial tools affect patients. Have a clear, honest narrative about how your technology improves patient outcomes—not just provider revenue.

The Bottom Line

The age of AI-driven claims denial is here—not as a pilot program or a proof of concept, but as an operational reality affecting millions of patients across the United States. Medicare’s Wasteful and Inappropriate Service Reduction Model is screening claims in six states. Private insurers are denying 1 in 4 claims at some plans. Sixty-one percent of physicians say AI is making prior authorization worse. Three states have passed laws drawing lines around what AI can and cannot do. And Mayo Clinic has already demonstrated that fighting bots with bots saves real money.

For healthcare IT trade show exhibitors, this is not a future trend to monitor—it is a present reality to address. HIMSS next month will be the first major test of whether the industry’s vendors have caught up to the speed of change. AHIP, HFMA, and ViVE will follow throughout the year, each examining a different facet of the same transformation. The exhibitors who win in 2026 will be those who understood that the battle of the bots is not just a clever nickname—it is the defining competitive dynamic of modern healthcare IT.

The algorithms are already running. The denials are already issuing. The only question is whether your show floor strategy is ready for the fight.